- Home
- AVD vs PLRX Comparison
AVD vs PLRX Comparison
Compare AVD & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVD | PLRX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVD | PLRX |
|---|---|---|
| Price | $4.95 | $1.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 11 |
| Target Price | ★ $12.00 | $3.79 |
| AVG Volume (30 Days) | 179.8K | ★ 906.7K |
| Earning Date | 03-13-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,073,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.28 | $1.10 |
| 52 Week High | $6.33 | $12.88 |
Technical Indicators
Market Signals| Indicator | AVD | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 75.09 | 50.00 |
| Support Level | $4.16 | $1.26 |
| Resistance Level | $3.94 | $1.38 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 84.83 | 55.88 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.